宗旨和范围
Drug Design, Development and Therapy is a peer-reviewed medical journal covering research on drug design and development through to clinical applications. The journal was established in 2007 and is published by Dove Medical Press. Less
关键指标
期刊详情
Indexed in the following public directories
- Web of Science
- Scopus
- DOAJ
- SJR
- 出版商DOVE MEDICAL PRESS LTD
- 出版语言English
- 出版频率Continuous publication
- 论文处理费USD 2836
- 发行日期16
- 编辑审稿流程Anonymous peer review
- 出版语言English
- 出版频率Continuous publication
- 创刊年份2007
- Publisher URL
- 网址
- 反剽窃政策
- 发行日期16
- 费用豁免政策
- 编辑团队
- 审稿流程Anonymous peer review
- 审稿信息网址
- Author instructions
- 版权详情
- 存档政策Sherpa/Romeo
- 许可证类型CC BY, CC BY-NC
- 开放获取申明
准备好展示你的研究成果了吗?
解锁专业图文摘要的强大优势:
月数 | 发表论文百分比 |
---|---|
0-3 | 20% |
4-6 | 71% |
7-9 | 9% |
>9 | 0% |
Topics Covered
常见问题
Drug Design, Development and Therapy 是从何时开始发行的?
Drug Design, Development and Therapy 自2007开始发行至今。
Drug Design, Development and Therapy 多久发行一次?
Drug Design, Development and Therapy 为Continuous publication。
Drug Design, Development and Therapy 的出版商是谁?
Drug Design, Development and Therapy 的出版商是DOVE MEDICAL PRESS LTD。
我在哪里查看 Drug Design, Development and Therapy 的宗旨和范围?
查看 Drug Design, Development and Therapy 的宗旨和范围,请点击此处。
我如何在意得辑上查看Drug Design, Development and Therapy 的指标?
查看 Drug Design, Development and Therapy 的指标,请单击此处。
Drug Design, Development and Therapy 的 eISSN和pISSN 号分别是什么?
1177-8881 的 eISSN 为 1177-8881,pISSN 为 Drug Design, Development and Therapy 。
该期刊重点关注哪些主题?
本期刊关注的主题范围广泛,包括 Cancer, Oxidative stress, Lidocaine, Toxicity, Clinical trial, Anti-inflammatory, Myocardial infarction, Reactive oxygen species, Dexamethasone, Western blot, Quercetin, Superoxide dismutase, Autophagy, Lung, Hepatocellular carcinoma, Curcumin, Osteoporosis, Femoral head, Xanthone, Lung cancer。
为什么搜索适合我研究的期刊很重要?
选择与您研究领域紧密相关的期刊,有助于确保您的学术成果能够触及最合适的读者群体, 从而最大化您的学术影响力和对该领域的贡献。
对期刊的选择会影响我的学术事业吗?
当然。在知名期刊上发表论文可提升您的学术形象, 使您在获取资助、终身教职和其他职业机会方面更具竞争力。
只考虑具有高影响力的期刊是否明智?
虽然高影响力的期刊知名度高,但投稿竞争也相对激烈。因此, 关键在于权衡考虑期刊的影响因子与论文被接受的可能性。